Lupin Somerset facility gets EIR from USFDA
Global pharma major, Lupin Limited, today announced that the company has received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA) for its Somerset, NJ manufacturing facility, after the inspection of the facility in March 2022.Voluntary Action Indicated (VAI) means objectionable conditions or practices were found but the agency is not prepared...
Global pharma major, Lupin Limited, today announced that the company has received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA) for its Somerset, NJ manufacturing facility, after the inspection of the facility in March 2022.
Voluntary Action Indicated (VAI) means objectionable conditions or practices were found but the agency is not prepared to take or recommend any administrative or regulatory action
For more details, check out the full details on the link below:
Lupin Gets USFDA EIR For Somerset Facility
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd